构建更优的哌拉西林-他唑巴坦药敏试验方法：谈何容易（这很复杂）。
Building a Better Test for Piperacillin-Tazobactam Susceptibility Testing: Would that It Were So Simple (It's Complicated).
机构信息
University of Queensland Centre for Clinical Research, Brisbane, Australia.
Infection Management Services, Princess Alexandra Hospital, Brisbane, Australia.
出版信息
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01649-19.
Abstract
In this issue of the , S. García-Fernandez, Y. Bala, T. Armstrong, M. Garcia-Castillo, et al. (J Clin Microbiol 58:e01042-19, 2020, https://doi.org/10.1128/JCM.01042-19) describe the performance of a reformulated Etest for piperacillin-tazobactam. The analytical performance data are excellent, but in the face of recent emerging data on the inefficacy of piperacillin-tazobactam for certain organisms that test susceptible, the value of piperacillin-tazobactam MICs is controversial. Evaluation of MICs in the context of the modal MIC for and , the variability of MIC tests, and, possibly, resistance mechanisms is important to the optimum use of this antimicrobial.
摘要
在本期《临床微生物学杂志》中，S. García-Fernandez、Y. Bala、T. Armstrong、M. Garcia-Castillo 等人（J Clin Microbiol 58:e01042-19, 2020, https://doi.org/10.1128/JCM.01042-19）描述了哌拉西林他唑巴坦的改良 Etest 的性能。分析性能数据非常出色，但面对最近关于某些测试敏感的生物体中哌拉西林他唑巴坦无效的新出现的数据，哌拉西林他唑巴坦 MIC 值的价值存在争议。在 和 的模式 MIC 背景下评估 MIC 值、MIC 测试的可变性，以及可能的耐药机制，对于合理使用这种抗菌药物非常重要。
相似文献
1
Building a Better Test for Piperacillin-Tazobactam Susceptibility Testing: Would that It Were So Simple (It's Complicated).构建更优的哌拉西林-他唑巴坦药敏试验方法：谈何容易（这很复杂）。
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01649-19.
2
Strategies for Updating Piperacillin-Tazobactam Breakpoints.哌拉西林-他唑巴坦折点更新策略。
J Clin Microbiol. 2023 Apr 20;61(4):e0004223. doi: 10.1128/jcm.00042-23. Epub 2023 Mar 15.
3
Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of , , and Complex.多中心评估新 Etest 梯度扩散法检测产 ESBL 肠杆菌科细菌对哌拉西林-他唑巴坦药敏试验的准确性
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01042-19.
4
Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.使用蒙特卡洛分析对持续输注哌拉西林/他唑巴坦针对铜绿假单胞菌的药效学特征进行分析。
Diagn Microbiol Infect Dis. 2002 Sep;44(1):51-7. doi: 10.1016/s0732-8893(02)00416-9.
5
In vitro susceptibility of multi-drug resistant Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolated from clinical specimens at Bugando Medical Centre, Tanzania to Piperacillin-Tazobactam.从坦桑尼亚布甘多医疗中心临床标本中分离出的耐多药铜绿假单胞菌和产超广谱β-内酰胺酶肺炎克雷伯菌对哌拉西林-他唑巴坦的体外敏感性
Tanzan J Health Res. 2014 Jan;16(1):54-7. doi: 10.4314/thrb.v16i1.8.
6
Argentinean collaborative multicenter study on the in vitro comparative activity of piperacillin-tazobactam against selected bacterial isolates recovered from hospitalized patients.阿根廷关于哌拉西林-他唑巴坦对从住院患者中分离出的特定细菌菌株的体外比较活性的多中心合作研究。
Diagn Microbiol Infect Dis. 2003 Nov;47(3):527-37. doi: 10.1016/s0732-8893(03)00131-7.
7
Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.哌拉西林-他唑巴坦时间超过 MIC 对铜绿假单胞菌菌血症结局的预测作用。
Antimicrob Agents Chemother. 2020 Jul 22;64(8). doi: 10.1128/AAC.02571-19.
8
Prediction of piperacillin-tazobactam susceptibility among Enterobacteriaceae, Pseudomonas aeruginosa, and other bacteria using ticarcillin-clavulanic acid, ceftazidime, and other broad-spectrum antimicrobial in vitro test results.利用替卡西林-克拉维酸、头孢他啶及其他广谱抗菌药物的体外试验结果预测肠杆菌科细菌、铜绿假单胞菌及其他细菌对哌拉西林-他唑巴坦的敏感性
Diagn Microbiol Infect Dis. 1994 Nov;20(3):143-9. doi: 10.1016/0732-8893(94)90108-2.
9
Comparative in vitro activity of Meropenem, Imipenem and Piperacillin/tazobactam against 1071 clinical isolates using 2 different methods: a French multicentre study.美罗培南、亚胺培南和哌拉西林/他唑巴坦对 1071 株临床分离菌的体外比较活性：一项法国多中心研究。
BMC Infect Dis. 2010 Mar 18;10:72. doi: 10.1186/1471-2334-10-72.
10
Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.铜绿假单胞菌对哌拉西林和哌拉西林-他唑巴坦药敏试验的自动化和手动系统的准确性
New Microbiol. 2011 Jan;34(1):97-9. Epub 2011 Jan 15.
引用本文的文献
1
Evaluation of MicroScan and VITEK 2 systems for susceptibility testing of Enterobacterales with updated breakpoints.使用更新后的断点评估MicroScan和VITEK 2系统对肠杆菌科细菌进行药敏试验的情况。
J Clin Microbiol. 2025 Jun 11;63(6):e0004825. doi: 10.1128/jcm.00048-25. Epub 2025 Apr 30.
2
Delving into discrepancies, a single-center experience with Accelerate Pheno for gram-negative bacteremia, a rapid phenotypic susceptibility testing method.深入探讨差异，关于Accelerate Pheno用于革兰氏阴性菌血症的单中心经验，一种快速表型药敏试验方法。
Antimicrob Steward Healthc Epidemiol. 2025 Jan 23;5(1):e15. doi: 10.1017/ash.2024.482. eCollection 2025.
3
Evaluation of piperacillin-tazobactam disks using contemporary Enterobacterales isolates suggests the need for disk potency optimization.使用当代肠杆菌科分离株对哌拉西林-他唑巴坦纸片进行评估表明需要对纸片效力进行优化。
J Clin Microbiol. 2025 Feb 19;63(2):e0159924. doi: 10.1128/jcm.01599-24. Epub 2025 Jan 10.
4
A multicenter evaluation of a novel microfluidic rapid AST assay for Gram-negative bloodstream infections.一种新型微流控快速 AST 检测法对革兰氏阴性菌血流感染的多中心评估
J Clin Microbiol. 2024 Oct 16;62(10):e0045824. doi: 10.1128/jcm.00458-24. Epub 2024 Sep 26.
5
Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing.肠杆菌科细菌哌拉西林/他唑巴坦敏感性试验的解释标准：美国抗菌药物敏感性试验委员会的建议
Clin Infect Dis. 2024 Dec 17;79(6):1354-1362. doi: 10.1093/cid/ciae328.
6
Clinical application of Vitek-derived minimum inhibitory concentration values: Proof of concept study.Vitek衍生的最低抑菌浓度值的临床应用：概念验证研究。
S Afr J Infect Dis. 2023 Mar 31;38(1):498. doi: 10.4102/sajid.v38i1.498. eCollection 2023.
7
Association between piperacillin/tazobactam MIC and survival among hospitalized patients with Enterobacterales infections: retrospective cohort analysis of electronic health records from 161 US hospitals.哌拉西林/他唑巴坦最低抑菌浓度与肠杆菌科感染住院患者生存率之间的关联：对美国161家医院电子健康记录的回顾性队列分析
JAC Antimicrob Resist. 2023 Apr 6;5(2):dlad041. doi: 10.1093/jacamr/dlad041. eCollection 2023 Apr.
8
Pragmatic Comparison of Piperacillin/Tazobactam versus Carbapenems in Treating Patients with Nosocomial Pneumonia Caused by Extended-Spectrum β-Lactamase-Producing .哌拉西林/他唑巴坦与碳青霉烯类药物治疗产超广谱β-内酰胺酶所致医院获得性肺炎患者的实用性比较
Antibiotics (Basel). 2022 Oct 10;11(10):1384. doi: 10.3390/antibiotics11101384.
9
Disk Correlates for Revised Clinical and Laboratory Standards Institute Piperacillin-Tazobactam MIC Breakpoints.针对修订后的临床和实验室标准协会哌拉西林-他唑巴坦最低抑菌浓度（MIC）断点的磁盘相关性
J Clin Microbiol. 2022 May 18;60(5):e0024322. doi: 10.1128/jcm.00243-22. Epub 2022 Apr 21.
10
Performance of dRAST on Prospective Clinical Blood Culture Samples in a Simulated Clinical Setting and on Multidrug-Resistant Bacteria.dRAST 在模拟临床环境中的前瞻性临床血培养样本和多药耐药菌中的性能。
Microbiol Spectr. 2022 Apr 27;10(2):e0210721. doi: 10.1128/spectrum.02107-21. Epub 2022 Mar 2.
本文引用的文献
1
Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of , , and Complex.多中心评估新 Etest 梯度扩散法检测产 ESBL 肠杆菌科细菌对哌拉西林-他唑巴坦药敏试验的准确性
J Clin Microbiol. 2020 Jan 28;58(2). doi: 10.1128/JCM.01042-19.
2
Point-Counterpoint: Differences between the European Committee on Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute Recommendations for Reporting Antimicrobial Susceptibility Results.观点对质：欧洲抗菌药物敏感性试验委员会与临床和实验室标准协会关于报告抗菌药物敏感性试验结果的推荐意见之间的差异。
J Clin Microbiol. 2019 Aug 26;57(9). doi: 10.1128/JCM.01129-19. Print 2019 Sep.
3
OXA-1 β-lactamase and non-susceptibility to penicillin/β-lactamase inhibitor combinations among ESBL-producing Escherichia coli.产超广谱β-内酰胺酶大肠埃希菌的 OXA-1β-内酰胺酶与对青霉素/β-内酰胺酶抑制剂合剂的不敏感性。
J Antimicrob Chemother. 2019 Feb 1;74(2):326-333. doi: 10.1093/jac/dky453.
4
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.哌拉西林-他唑巴坦与美罗培南对产 ESBLs 的大肠埃希菌或肺炎克雷伯菌血流感染且对头孢曲松耐药患者 30 天死亡率的影响：一项随机临床试验。
JAMA. 2018 Sep 11;320(10):984-994. doi: 10.1001/jama.2018.12163.
5
Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.β-内酰胺/β-内酰胺酶抑制剂与碳青霉烯类药物治疗产超广谱β-内酰胺酶肠杆菌科血流感染的疗效比较：系统评价和荟萃分析。
Int J Antimicrob Agents. 2018 Nov;52(5):554-570. doi: 10.1016/j.ijantimicag.2018.07.021. Epub 2018 Aug 3.
6
MIC-based dose adjustment: facts and fables.基于 MIC 的剂量调整：事实与虚构。
J Antimicrob Chemother. 2018 Mar 1;73(3):564-568. doi: 10.1093/jac/dkx427.
7
Piperacillin-Tazobactam versus Other Antibacterial Agents for Treatment of Bloodstream Infections Due to AmpC β-Lactamase-Producing Enterobacteriaceae.哌拉西林-他唑巴坦与其他抗菌药物治疗产AmpCβ-内酰胺酶肠杆菌科细菌所致血流感染的比较
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00276-17. Print 2017 Jun.
8
Pharmacokinetic evaluation of piperacillin-tazobactam.哌拉西林-他唑巴坦的药代动力学评价。
Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):1017-31. doi: 10.1517/17425255.2010.506187.
Zotero 插件